The downregulation of PPARGC1A in HCC and also resistance of HCC cells to lenvatininb were due to N6-Methyladenosine (m6A) modification of PPARGC1A mRNA by methyltransferase 3 (METTL3), a key m6A writer that they found highly expressed in HCC. Here, PPARGC1A is linked to hepatocellular carcinoma.